RedFlag Index™ · #5 of 10 · NYSE: JNJ

Johnson & Johnson: enforcement record and regulatory exposure

Johnson & Johnson scores 62 out of 100 on the RedFlag Index™ (October 2026), ranking #5 of ten tracked companies, with 4 documented cases of which 3 remain open.

Johnson & Johnson has paid about $25.1 billion in tracked penalties since 2000, the highest in this set.

2024: Johnson & Johnson paid $700 million to 42 states and D.C. over talc marketing.

2021–2022: Janssen, a Johnson & Johnson subsidiary, agreed to pay up to $5 billion in the national opioid settlement.

2021: Johnson & Johnson recorded about $800 million to resolve roughly 9,000 Risperdal gynecomastia cases.

2013: Johnson & Johnson paid $2.2 billion over Risperdal, Invega, and Natrecor, including about $485 million in criminal fines and forfeiture.

2013: DePuy, a Johnson & Johnson subsidiary, agreed to a $2.5 billion hip-implant settlement.

  1. Opioid Litigation

    AbbVie bought Allergan and inherited an opioid bill of up to $2.37 billion.

    Allergan had sold its generic opioid business years earlier. The liability stayed, and the settlement carries no admission.

  2. State Enforcement

    Johnson & Johnson pays $700 million to states over talc powder marketing

    Johnson & Johnson agreed to a $700 million settlement with 42 states and the District of Columbia resolving allegations that it deceptively marketed talc-based baby and body powders. The consent judgments permanently bar J&J from making or selling talc-based powders in the United States.

  3. Drug Pricing

    Federal judge rejects Merck's constitutional challenge to Medicare drug price negotiation

    Judge Colleen Kollar-Kotelly of the US District Court for the District of Columbia rejected Merck's First and Fifth Amendment challenge to the Inflation Reduction Act's Medicare drug price negotiation programme. Merck filed the first industry challenge to the programme in June 2023.